Compare SGU & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGU | ZURA |
|---|---|---|
| Founded | 1995 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 422.1M | 407.0M |
| IPO Year | 1997 | N/A |
| Metric | SGU | ZURA |
|---|---|---|
| Price | $13.04 | $6.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 28.1K | ★ 353.1K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.67% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,784,418,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.70 | ★ N/A |
| Revenue Growth | ★ 1.04 | N/A |
| 52 Week Low | $11.31 | $0.99 |
| 52 Week High | $13.75 | $6.88 |
| Indicator | SGU | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.83 | 56.16 |
| Support Level | $12.66 | $5.78 |
| Resistance Level | $13.05 | $6.40 |
| Average True Range (ATR) | 0.31 | 0.47 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 41.09 | 45.74 |
Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.